Hepatitis C virus infection

This early-stage trial tests a DNA vaccine called INO-8000, given with an immune booster, to see if it can help people with chronic hepatitis C fight the virus. The study involves 33 participants and focuses on safety and finding the best dose. The vaccine is delivered through in…

This study is testing a special kiosk placed in rural Appalachian Kentucky that provides clean syringes and harm reduction supplies to people who inject drugs. The goal is to see if the kiosk helps reduce the spread of HIV and hepatitis C, and lowers the risk of drug overdose. Ab…

This study tests a new two-drug combination, BEM/RZR, against an approved treatment, SOF/VEL, in 880 adults with chronic hepatitis C. The goal is to see if BEM/RZR can clear the virus as effectively and safely. Participants must not have taken prior HCV drugs and may have compens…

This study tests whether using a dried blood spot test (a simple finger prick) can help people with hepatitis C start treatment faster than the usual method that requires a blood draw. The trial involves 141 participants who work with a peer support program and telemedicine. The …

This study tests whether lungs from donors with hepatitis C can be safely transplanted into people without the virus. The lungs are treated with a special machine to try to reduce the virus. If the recipient gets infected, they will be treated with standard antiviral medication. …

This study tests a 12-week course of three antiviral drugs (sofosbuvir, velpatasvir, and voxilaprevir) in 200 adults with chronic hepatitis C whose virus returned after previous treatment. The main goal is to see if the virus becomes undetectable 12 weeks after therapy ends. Rese…

This study tests whether peer mentors—people with similar experiences—can help individuals recently released from jail or prison get connected to Hepatitis C care and stay in treatment. About 80 participants will either receive a peer mentor or standard referral. The goal is to s…

This study tests a 12-week course of the drug Sofosbuvir/Velpatasvir in about 100 pregnant women with chronic hepatitis C. The goal is to see if the treatment can cure the virus and whether it affects the timing of delivery. Mothers are followed for 12 weeks after treatment, and …

This study tests a program where trained peers use motivational interviewing to encourage people who use drugs to check their drugs for dangerous substances and adopt safer use behaviors. The goal is to reduce fatal and non-fatal overdoses, as well as HIV and hepatitis C infectio…

This study follows 30 adults with chronic hepatitis C (genotype 3) and mild to moderate liver fibrosis who are taking ravidasvir and sofosbuvir as part of their regular care. Researchers will check if the virus is undetectable 12 weeks after treatment ends (SVR12). The goal is to…

This study is testing a combination of two antiviral drugs, sofosbuvir and daclatasvir, in children aged 6 and older with active hepatitis C in Cambodia. The goal is to see if the treatment can clear the virus from the blood 12 weeks after finishing the 12-week course. The trial …

This study is for people in Pakistan with hepatitis C who did not get cured by their first treatment. It compares two different lengths of treatment with the drug Epclusa (12 weeks vs 24 weeks) to see which works better. About 318 adults will take part, and the goal is to find th…

This study tests whether kidneys from donors with hepatitis C can be safely transplanted into people without the virus. Recipients will take the antiviral drug Epclusa for 12 weeks to prevent or treat infection. The goal is to see if this approach is safe and effective, potential…

This study aims to eliminate hepatitis C among people who use drugs in Paris, Marseille, Lyon, and Fort-de-France. Researchers will screen participants, provide immediate treatment, and use a peer-referral system to reach more people. The goal is to see if this community-based ap…

This study is testing whether adding a blood test called the GAAD score to regular ultrasound scans can improve the detection of liver cancer in people at high risk, such as those with cirrhosis or chronic hepatitis. About 2,100 participants will get both tests every six months f…

This pilot trial tests whether training Gancheros—people who provide injection services in exchange for money or drugs—can lower HIV, hepatitis C, and overdose risks among migrant Puerto Rican people who inject drugs in New York City. Gancheros will attend six sessions on prevent…

This study tests whether providing HIV prevention (PrEP) and hepatitis C treatment together at one location works better than sending patients to separate clinics. About 446 people who inject drugs will be randomly assigned to either on-site integrated care or off-site referrals …

This study tests whether a short course of two drugs (glecaprevir/pibrentasvir and ezetimibe) can prevent hepatitis C infection in people who receive a kidney, heart, lung, or pancreas from a donor with hepatitis C. About 200 participants who are hepatitis C-negative will take th…

Researchers are testing a coaching program to help primary care clinics in rural West Virginia screen and treat opioid use disorder, HIV, and hepatitis C. The program includes group priority-setting, rapid-cycle improvement coaching, and provider training. Twenty clinics will tak…

This study follows 121 adults who have been cured of chronic hepatitis C to understand why some still develop liver complications like scarring or cancer. Participants are monitored for up to 10 years with regular tests, scans, and occasional liver biopsies. The goal is to learn …

This study looks at liver health in transgender people who are on gender-affirming hormone therapy (GAHT). It compares those who have been on hormones for more than six months with those on them for less time. Researchers will measure liver function through blood tests and a spec…

This study follows people with chronic hepatitis B or C for up to 10 years to track how the disease changes over time. A smaller group with hepatitis B will receive the drug tenofovir alafenamide for 2 years to see if it reduces liver stiffness. Participants provide blood samples…

This study tests a program where veteran peer workers provide education, healthcare navigation, and social support to 150 veterans with opioid use disorder who are not connected to VA healthcare. The goal is to reduce risky behaviors related to overdose and HIV/HCV infection. Res…

This study planned to see if faster testing and treatment for hepatitis C could be given to inmates right when they enter prison. The goal was to start medication sooner to reduce the spread of the virus. However, the study was withdrawn and no one took part.

This study looks at immune cells from people with autoimmune diseases (like lupus), people with infections, and healthy volunteers. Researchers want to understand how these cells differ and what makes them attack the body in autoimmune conditions. The study involves blood and bon…